D. Boral Capital Reiterates "Buy" Rating for VolitionRx (NYSE:VNRX)

Key Points

• D. Boral Capital has reaffirmed a "Buy" rating for VolitionRx (NYSE: VNRX) with a price target of $5.00.
• The company's stock currently has a consensus rating of "Buy" among analysts, with a consensus price target of $3.50.
• Insider activity has increased, with both the CEO and a director purchasing shares, signaling confidence in the company's prospects.

VolitionRx (NYSE:VNRX - Get Free Report)'s stock had its "buy" rating restated by analysts at D. Boral Capital in a report issued on Wednesday,Benzinga reports. They presently have a $5.00 target price on the stock.

Several other analysts also recently commented on VNRX. Jones Trading raised shares of VolitionRx to a "strong-buy" rating and set a $3.00 price objective for the company in a research report on Tuesday, June 10th. Wall Street Zen initiated coverage on shares of VolitionRx in a research report on Thursday, May 15th. They set a "sell" rating for the company. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, VolitionRx presently has an average rating of "Buy" and a consensus target price of $3.50.

VolitionRx Stock Down 1.2%

VolitionRx stock traded down $0.01 during mid-day trading on Wednesday, hitting $0.65. 101,341 shares of the stock were exchanged, compared to its average volume of 197,892. The stock has a market capitalization of $69.72 million, a price-to-earnings ratio of -1.80 and a beta of 1.27. VolitionRx has a 12 month low of $0.40 and a 12 month high of $0.94. The firm's fifty day simple moving average is $0.67 and its two-hundred day simple moving average is $0.60.

Insiders Place Their Bets

In other news, Director Guy Archibald Innes acquired 78,125 shares of the business's stock in a transaction on Tuesday, August 5th. The shares were purchased at an average cost of $0.64 per share, with a total value of $50,000.00. Following the acquisition, the director directly owned 966,814 shares of the company's stock, valued at $618,760.96. The trade was a 8.79% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Cameron John Reynolds acquired 78,125 shares of the business's stock in a transaction on Tuesday, August 5th. The shares were purchased at an average cost of $0.64 per share, for a total transaction of $50,000.00. Following the completion of the acquisition, the chief executive officer directly owned 2,609,847 shares in the company, valued at approximately $1,670,302.08. The trade was a 3.09% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired a total of 171,250 shares of company stock worth $109,900 over the last ninety days. Insiders own 10.40% of the company's stock.

Hedge Funds Weigh In On VolitionRx

A number of hedge funds have recently bought and sold shares of the company. Armistice Capital LLC boosted its holdings in VolitionRx by 3.5% during the 2nd quarter. Armistice Capital LLC now owns 8,493,074 shares of the company's stock worth $6,455,000 after acquiring an additional 286,644 shares during the last quarter. Silverberg Bernstein Capital Management LLC boosted its holdings in VolitionRx by 42.8% during the 2nd quarter. Silverberg Bernstein Capital Management LLC now owns 200,782 shares of the company's stock worth $153,000 after acquiring an additional 60,209 shares during the last quarter. Northern Trust Corp raised its stake in shares of VolitionRx by 32.0% during the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company's stock worth $71,000 after purchasing an additional 28,579 shares during the period. Northwestern Mutual Wealth Management Co. bought a new stake in shares of VolitionRx during the 2nd quarter worth $52,000. Finally, Millennium Management LLC bought a new stake in shares of VolitionRx during the 4th quarter worth $36,000. 8.09% of the stock is owned by hedge funds and other institutional investors.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.